Reviewer’s report

Title: Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: A case report

Version: 0 Date: 29 Aug 2018

Reviewer: V. Koneti Rao

Reviewer's report:

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

It is a well written case report about LPD in a 70year old woman with h/o H. pylori and RA who developed LPD after being on MTX 6mg weekly for 6 months. I liked the schematic diagram of Figure 3.

1. Line 41, page 1: I am not sure I understand what authors mean when they say: "but chemotherapy based on tissue type is required in intractable or recurrent cases". It may be more appropriate to say "chemotherapy may be needed to treat lymphoma recurring or persisting after stopping MTX treatment".

2. Line 41: Lymphoma treatment does not depend on tissue type.

3. Line 54; Discussion page 1: Withdrawal of MTX results in spontaneous remission of LPD in 25-60% of cases. Please comment how long does the remission last and how many require further treatment with chemotherapy like your patient.

4. Line 22; Discussion page 2: Please add data if available about the incidence of lymphoma in RA patients following use of other agents in RA: Cyclosporine, Biologicals etc. Is it higher than baseline lymphoma rate in general population as well as RA patients not on these drugs?

5. Figure 3: Add SUV values for the serial PET scans, if available.

6. Table 1: Remove this table as it does not add much value since most values are normal except sIL2R (already nicely graphed in figure 3) and LDH.
Are the methods appropriate and well described? 
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls? 
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown? 
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review? 
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests 
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal